Table 3.

Univariate analysis of clinicopathological features with respect to breast cancer patients’ response to NCT.

			Clinical response				Pathological response
Clinicopathological features		Total	CR+PR(n)	PD+SD(n)	x2	P	pCR (n)	No-pCR (n)	x2	P
Age	<50	26	13	13	2.605	0.183	5	21	0.017	1.000
	≥50	28	20	8			5	23
Menopausal status	Pre-	28	20	8	2.605	0.183	5	23	0.017	1.000
	Post-	26	13	13			5	21
History of gravidity	No	7	5	2	0.360	0.693	2	5	0.539	0.601
	Yes	47	28	19			8	39
Family history of malignance	No	40	24	16	0.080	1.000	6	34	1.266	0.424
	Yes	14	9	5			4	10
Clinical T stage	T1, T2	23	18	5	4.958	0.047	8	15	7.024	0.012
	T3, T4	31	15	16			2	29
Clinical N stage	N0	13	8	5	0.001	1.000	5	8	4.513	0.048
	N1-N3	41	25	16			5	36
Clinical stage	I+II	14	8	6	0.125	0.758	3	11	0.106	0.708
	III+IV	40	25	15			7	33
Pathological T stage	pT0, T1, T2	43	30	13	6.656	0.015	8	34	0.814	0.667
	pT3, T4	11	3	8			2	10
Pathological N stage	pN0	9	5	4	0.140	0.708	0	9	2.455	0.183
	pN1-N3	45	28	17			10	35
Pathological TNM stage	I+II	18	10	8	0.351	0.569	3	15	0.061	1.000
	III+IV	36	23	13			7	29
Histological type	IDBC	44	27	17	0.006	0.936	7	37	1.072	0.370
	Other	10	6	4			3	7
ER	−	24	19	5	5.926	0.015	5	19	0.153	0.736
	+	30	14	16			5	25
PR	−	27	20	7	3.818	0.093	6	21	0.491	0.728
	+	27	13	14			4	23
Her-2	−	33	18	15	1.539	0.261	9	24	4.310	0.069
	+	21	15	6			1	20
Ki67	−	22	15	7	0.781	0.410	5	17	0.436	0.723
	+	32	18	14			5	27
P53	−	23	13	10	0.355	0.584	3	20	0.796	0.489
	+	21	20	11			7	24
Luminal type	Luminal	42	22	20	6.237	0.044	6	36	2.520	0.284
	Her-2	4	4	0			1	3
	Basal-like	8	7	1			3	5
Chemotherapy regime	TAC/TEC	39	26	13	1.834	0.100	6	33	1.747	0.418
	TA/TE	13	6	7			3	10
	Other	2	1	1			1	1
Chemotherapy cycles	2 cycles	39	27	12	3.895	0.065	5	34	3.021	0.119
	≥3 cycles	15	6	9			5	10

IDBC: Invasive ductal breast cancer; For categorical variables, the x² value and P value were calculated by Chi-square tests and Fisher's exact tests.